Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 28, 2013; 19(48): 9447-9452
Published online Dec 28, 2013. doi: 10.3748/wjg.v19.i48.9447
Published online Dec 28, 2013. doi: 10.3748/wjg.v19.i48.9447
Table 3 Acute adverse events in the two groups
| Acute adverse reactions | NDP group (n = 34) | DDP group (n = 34) | χ2 | P value | ||||||||||
| 0 | I | II | III | IV | Incidence | 0 | I | II | III | IV | Incidence | |||
| Hemoglobin | 14 | 9 | 5 | 5 | 1 | 58.80% | 16 | 8 | 5 | 4 | 1 | 52.90% | 0.303 | 0.990 |
| Leukopenia | 13 | 8 | 7 | 6 | 0 | 61.80% | 15 | 8 | 6 | 4 | 1 | 55.90% | 1.62 | 0.805 |
| Platelet | 15 | 7 | 6 | 5 | 1 | 55.90% | 20 | 4 | 7 | 3 | 0 | 41.20% | 3.109 | 0.540 |
| Bilirubin | 29 | 4 | 1 | 0 | 0 | 14.70% | 30 | 3 | 1 | 0 | 0 | 11.80% | 0.16 | 0.923 |
| Transaminase | 25 | 8 | 1 | 0 | 0 | 26.50% | 27 | 7 | 0 | 0 | 0 | 20.60% | 1.144 | 0.565 |
| Urea nitrogen | 30 | 4 | 0 | 0 | 0 | 11.80% | 29 | 3 | 2 | 0 | 0 | 14.70% | 2.16 | 0.340 |
| Creatinine | 31 | 2 | 1 | 0 | 0 | 8.80% | 21 | 9 | 3 | 1 | 0 | 38.20% | 8.378 | 0.039 |
| Nausea | 28 | 4 | 1 | 1 | 0 | 17.60% | 17 | 7 | 6 | 4 | 0 | 50.00% | 8.878 | 0.031 |
| Vomiting | 30 | 2 | 1 | 1 | 0 | 11.80% | 18 | 6 | 4 | 6 | 0 | 47.10% | 10.371 | 0.016 |
| Esophagitis | 8 | 18 | 7 | 1 | 0 | 76.50% | 4 | 19 | 9 | 1 | 1 | 88.20% | 2.61 | 0.625 |
| Pneumonia | 18 | 14 | 2 | 0 | 0 | 47.10% | 12 | 17 | 4 | 1 | 0 | 64.70% | 3.157 | 0.368 |
- Citation: Shen ZT, Wu XH, Li B, Shen JS, Wang Z, Li J, Zhu XX. Nedaplatin concurrent with three-dimensional conformal radiotherapy for treatment of locally advanced esophageal carcinoma. World J Gastroenterol 2013; 19(48): 9447-9452
- URL: https://www.wjgnet.com/1007-9327/full/v19/i48/9447.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i48.9447